Oncolytic virus-derived type I interferon restricts CAR T cell therapy

The application of adoptive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinatorial strategies to overcome immune suppression associated with the tumor microenvironment. Here we test whether the inflammatory nature of oncolytic...

Descripción completa

Detalles Bibliográficos
Autores principales: Evgin, Laura, Huff, Amanda L., Wongthida, Phonphimon, Thompson, Jill, Kottke, Tim, Tonne, Jason, Schuelke, Matthew, Ayasoufi, Katayoun, Driscoll, Christopher B., Shim, Kevin G., Reynolds, Pierce, Monie, Dileep D., Johnson, Aaron J., Coffey, Matt, Young, Sarah L., Archer, Gary, Sampson, John, Pulido, Jose, Perez, Luis Sanchez, Vile, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314766/
https://www.ncbi.nlm.nih.gov/pubmed/32581235
http://dx.doi.org/10.1038/s41467-020-17011-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314766/
https://www.ncbi.nlm.nih.gov/pubmed/32581235
http://dx.doi.org/10.1038/s41467-020-17011-z

Ejemplares similares